Bristol-Myers Squibb in heart drug collaboration
Published: 04 Mar 2009 18:33:15 PSTNEW YORK, March 4 - Bristol-Myers Squibb on Wednesday announced a collaboration with Nissan Chemical Industries Ltd and Teijin Pharma Ltd for the development and commercialization of a drug to help maintain normal sinus rhythm in patients with atrial fibrillation.
The drug, NTC-801, is under development in Japan.
An upfront cash payment of $40 million, potential development-based milestones of up to $170 million, sales-based milestones of up to $175 million and royalties are payable by Bristol-Myers Squibb.
Go to Page
Page 1 of 1
1
Source:
Reuters
If you believe an article violates your rights or the rights of others, please contact us.
Digg
Reddit
Mixx it
FacebookRelated News
Most Read
- 1BYD Auto to expand into solar energy field
- 2Entrepreneurblues
- 3AUTOSHOW-INTERVIEW-UPDATE 1-Changan Ford Mazda
- 4ANALYSIS-CFTC cautious on position limits, set
- 5Beyond The Anti-Virus Arms Race
- 6Beware of phishing scams if you are using
- 7Help protect yourself from phishing scams and
- 8Xi'an to launch industrial zone
- 9China Longyuan Power plans HK$17.5-bln HK IPO
- 10INTERVIEW-StanChart eyes $800 mln in renewable
